OncoMatch/Clinical Trials/NCT06866964
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Is NCT06866964 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Low-dose ASA for germ cell tumor.
Treatment: Low-dose ASA — The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
Check if I qualifyExtracted eligibility criteria
Cancer type
Testicular Germ Cell Tumor
Disease stage
Required: Stage IS, IIA, IIB, IIC, III, IIIA, IIIB, IIIC (AJCC 8th edition)
Histological confirmation of stage IS or IIA or higher testicular or germ cell cancer. Stage IIC or III or higher per AJCC 8th edition criteria.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: adjuvant setting
Receiving chemotherapy in adjuvant setting
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Charlotte, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
- Aurora St. Luke's Medical Center MOB · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify